Imaging Pattern of Diffuse Intrapulmonary Metastases in Lung Cancer Was Associated with Poor Prognosis to Epidermal Growth Factor Receptor Inhibitors

Imaging Pattern of Diffuse Intrapulmonary Metastases in Lung Cancer Was Associated with Poor Prognosis to Epidermal Growth Factor Receptor Inhibitors

Yang Fu,1 Yuan Tang,2 Yue Zheng,1 Yue-Yun Chen,1 Ye Hong,1 Pei-Pei Wang,1 Qing Li,1 Ting Liu,1 Zhen-Yu Ding1 1Department of Biotherapy, Cancer Center, West China Hospital, West China Medical School, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, People’s Republic of China...

Full description

Bibliographic Details
Main Authors:	Fu Y, Tang Y, Zheng Y, Chen YY, Hong Y, Wang PP, Li Q, Liu T, Ding ZY
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-11-01
Series:	Cancer Management and Research
Subjects:	epidermal growth factor receptor egfr tyrosine kinase inhibitor tki ct imaging outcome genetic aberration
Online Access:	https://www.dovepress.com/imaging-pattern-of-diffuse-intrapulmonary-metastases-in-lung-cancer-wa-peer-reviewed-article-CMAR

Similar Items

Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR)
by: Nichole E. M. Kaufman, et al.
Published: (2021-02-01)

Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations
by: Zhang R, et al.
Published: (2016-01-01)

Durable response to EGFR tyrosine kinase inhibitors in a patient with non–small cell lung cancer harboring an EGFR kinase domain duplication
by: Esuteru Hirokawa, et al.
Published: (2021-08-01)

Advances in the Research of Autophagy in EGFR-TKI Treatment and Resistance  in Lung Cancer
by: Qicheng ZHANG, et al.
Published: (2016-09-01)

Continuous EGFR tyrosine kinase inhibitor treatment with or without chemotherapy beyond gradual progression in non-small cell lung cancer patients
by: Peng L, et al.
Published: (2017-08-01)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
by: Ping-Chih Hsu, et al.
Published: (2020-10-01)

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
by: Wen-Shuo Wu, et al.
Published: (2014-06-01)

A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition
by: Nana Zhang, et al.
Published: (2017-01-01)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
by: Wu Z, et al.
Published: (2019-10-01)

Third-Generation TKI Resistance Due to SCLC Transformation: A Case Report and Brief Review
by: Chen S, et al.
Published: (2019-12-01)

Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC
by: Sangtian Liu, et al.
Published: (2021-03-01)

Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future
by: Walid Shalata, et al.
Published: (2021-08-01)

Effect of β-Blocker in Treatment-Naïve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs
by: Chia-Hao Chang, et al.
Published: (2020-10-01)

Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death
by: Ping Chen, et al.
Published: (2019-06-01)

Concurrent chemotherapy and first‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first‐line treatment in advanced lung adenocarcinoma harboring an EGFR mutation
by: Ziyi Xu, et al.
Published: (2021-08-01)

Management of Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs
by: Barbara eMelosky, et al.
Published: (2014-09-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
by: Yi-fan Chen, et al.
Published: (2011-12-01)

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
by: Masayuki Takeda, et al.
Published: (2019-01-01)

Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis
by: Limin CHEN, et al.
Published: (2019-05-01)

Diffuse Hypopigmentation Followed by Hyperpigmentation in an African American Woman with Hemangiopericytoma Treated with Dasatinib
by: Karim Boudadi, et al.
Published: (2014-11-01)

Study of the Correlation of EGFR and K-RAS Gene Mutations with Its Protein Expression in Non-small Cell Lung Cancer
by: Huan-ling LUAN, et al.
Published: (2010-04-01)

The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma
by: Ping-Chih Hsu, et al.
Published: (2020-02-01)

Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations
by: Yutaka Yamada, et al.
Published: (2021-09-01)

Next‐generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non‐small cell lung cancer
by: Yujun Zhang, et al.
Published: (2021-07-01)

Progress toward resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitor
by: Zhang Lingling, et al.
Published: (2016-01-01)

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
by: Niki Karachaliou, et al.
Published: (2014-09-01)

Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer
by: Gao Y, et al.
Published: (2015-12-01)

Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy
by: Yulong Fu, et al.
Published: (2021-02-01)

CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)
by: Qiong Qin, et al.
Published: (2020-09-01)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
by: Guo-Hao Xia, et al.
Published: (2014-12-01)

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management
by: Akhil Rajendra, et al.
Published: (2019-01-01)

Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation—A Case Report and a Review of the Literature
by: Izumi Sato, et al.
Published: (2020-08-01)

Research Progress of EGFR-TKI Therapy for Patients with Central Nervous System  Metastases from Non-small Cell Lung Cancer
by: Yinghua JIN, et al.
Published: (2016-08-01)

Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling
by: Naoyuki Nishiya, et al.
Published: (2019-11-01)

The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations
by: Yongdong Feng, et al.
Published: (2021-05-01)

Lung adenocarcinoma presents with diffuse bone metastasis
by: Jinye Mi, et al.
Published: (2021-10-01)

Neutrophil-to-Lymphocyte Ratio is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy
by: Nicole K. Yun, et al.
Published: (2021-03-01)

Redox-dependent regulation of epidermal growth factor receptor signaling
by: David E. Heppner, et al.
Published: (2016-08-01)

Optimal Therapeutic Strategy for Non-small Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor
by: Zhong SHI, et al.
Published: (2015-02-01)

Significant Benefits of Afatinib and Apatinib in a Refractory Advanced NSCLC Patient Resistant to Osimertinib: A Case Report
by: Zhao Y, et al.
Published: (2021-05-01)

Cannot write session to /tmp/vufind_sessions/sess_cd0chd5hst2o2475344eah7dj5